Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 25Lymphoma 13Leukemia, Myeloid, Acute 10Ovarian Neoplasms 9Neoplasm Metastasis 9Lymphoma, Follicular 9Leukemia 9Stomach Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neuroblastoma 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lymphoma, B-Cell, Marginal Zone 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 5Kidney Neoplasms 5Hodgkin Disease 5Burkitt Lymphoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Triple Negative Breast Neoplasms 4Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

pembrolizumab 2fludarabine 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Microsatellite Instability × aldesleukin × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡